Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we investiga...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Proc Natl Acad Sci U S A
Autori principali: Kloepper, Jonas, Riedemann, Lars, Amoozgar, Zohreh, Seano, Giorgio, Susek, Katharina, Yu, Veronica, Dalvie, Nisha, Amelung, Robin L., Datta, Meenal, Song, Jonathan W., Askoxylakis, Vasileios, Taylor, Jennie W., Lu-Emerson, Christine, Batista, Ana, Kirkpatrick, Nathaniel D., Jung, Keehoon, Snuderl, Matija, Muzikansky, Alona, Stubenrauch, Kay G., Krieter, Oliver, Wakimoto, Hiroaki, Xu, Lei, Munn, Lance L., Duda, Dan G., Fukumura, Dai, Batchelor, Tracy T., Jain, Rakesh K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2016
Soggetti:
Biological Sciences
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4843473/
https://ncbi.nlm.nih.gov/pubmed/27044098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1525360113
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi